Evidence map›Paper›PMID 36102309›Full record

ArticleMolecular medicine reports2022

Activating transcription factor 3 inhibits angiotensin II‑induced cardiomyocyte viability and fibrosis by activating the transcription of cysteine‑rich angiogenic protein 61.

Yu Zhang, Heming Wu, Honghui Luo, Yiqun Luo, Cong Huang

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yu ZhangDepartment of General Practice, Meizhou People's Hospital, Meizhou, Guangdong 514031, P.R. China.
Heming WuCentral Laboratory, Meizhou People's Hospital, Meizhou, Guangdong 514031, P.R. China.
Honghui LuoDepartment of General Practice, Meizhou People's Hospital, Meizhou, Guangdong 514031, P.R. China.
Yiqun LuoDepartment of General Practice, Meizhou People's Hospital, Meizhou, Guangdong 514031, P.R. China.
Cong HuangDepartment of General Practice, Meizhou People's Hospital, Meizhou, Guangdong 514031, P.R. China.
Meizhou City People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depletion of activating transcription factor 3 (ATF3) expression has previously been reported to promote hypertrophy, dysfunction and fibrosis in stress overload‑induced hearts; however, the mechanism involved remains poorly understood. In the present study, the mechanism underlying the activation of cysteine‑rich angiogenic protein 61 (Cyr61) by ATF3 in hyperproliferative and fibrotic human cardiac fibroblasts (HCFs), induced by angiotensin II (Ang II), was evaluated. The mRNA and protein expression levels of ATF3 and Cyr61 were assessed using reverse transcription‑quantitative PCR and western blotting, respectively. The Cell Counting Kit‑8 assay was used to assess cell viability. Cell migration was assessed using the wound healing assay and western blotting, whereas the extent of cell fibrosis was evaluated using immunofluorescence staining and western blotting. The binding site of ATF3 to the Cyr61 promoter was predicted using the JASPAR database, and verified using luciferase reporter and chromatin immunoprecipitation assays. The results demonstrated that the mRNA and protein expression levels of ATF3 were significantly upregulated in Ang II‑induced HCFs. Overexpression of ATF3 significantly inhibited the Ang II‑induced viability, migration and fibrosis of HCFs, whereas ATF3 knockdown mediated significant opposing effects. Mechanistically, ATF3 was demonstrated to transcriptionally activate Cyr61. Cyr61 silencing was subsequently revealed to reverse the effects of ATF3 overexpression on HCFs potentially via regulation of the TGF‑β/Smad signaling pathway. The results of the present study suggested that ATF3 could suppress HCF viability and fibrosis via the TGF‑β/Smad signaling pathway by activating the transcription of Cyr61.

Indexed as

Angiotensin IIActivating Transcription Factor 3Angiogenic ProteinsCyclic AMP Response Element-Binding ProteinCysteineCysteine-Rich Protein 61FibrosisHumansMyocytes, CardiacRNA, MessengerTransforming Growth Factor betaActivating Transcription Factor 3Angiogenic ProteinsAngiotensin IIATF3 protein, humanCCN1 protein, humanCyclic AMP Response Element-Binding ProteinCysteineCysteine-Rich Protein 61RNA, MessengerTransforming Growth Factor betaactivating transcription factor 3angiotensin IIcardiac hypertrophycysteine‑rich angiogenic protein 61fibrosisproliferation

Identifiers

PMID36102309
PMCPMC9494611
OpenAlexW4295260828

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.